GORE® EXCLUDER® Iliac Branch Endoprosthesis Is First Dedicated System of Its Kind Approved in Europe
First Successful Implants Completed in Italy and the United Kingdom, Providing Endovascular Repair to Iliac Arteries
First Patients Enrolled in Gore Thoracoabdominal Aortic Aneurysm Clinical Study
Device offers first and only complete “off-the-shelf” endovascular system specifically designed to treat aortic aneurysms involving visceral branch vessels
Gore Again Named One of the 100 Best Companies to Work For®
Every year since 1998: That’s how long W. L. Gore & Associates has appeared on the Fortune 100 Best Companies to Work For® list
GORE® EXCLUDER® Iliac Branch Endoprosthesis Exceeds 1,000 Implants Worldwide
Innovative system for managing common iliac artery aneurysms or aortoiliac aneurysms impacting lives around the world
Gore Marks 20th Year on 100 Best Companies to Work For® List
Gore has appeared in every edition of the rankings, published annually in Fortune magazine. The company is among just 12 “Great Place to Work Legends” to hold this distinction.
Gore Announces First-in-Human Use of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System for TEVAR
New delivery system provides controlled and predictable placement of Gore’s highly conformable and time-tested stent graft
Gore Completes Patient Enrollment in U.S. Pivotal Clinical Study of GORE® CARDIOFORM ASD Occluder
New addition to GORE® CARDIOFORM Occluder family is designed to treat larger atrial septal defects by adapting to the patient’s anatomy for a permanent and safe closure
Celebrating the 20th Anniversary of the GORE® EXCLUDER® Device
With two decades of evolution and more than 300,000 patients treated* worldwide, this trusted, market-leading EVAR device continues to advance patient care
Gore Launches Anti-Migration Assurance Program for GORE® VIABIL® Short Wire Biliary Endoprosthesis
Device is proven to reduce the risk of reintervention for patients with pancreatic and other cancers that obstruct the bile duct; replacement program can help limit overall costs of palliative care